Abstract:The regulatory T (Treg) cells constitute a functionally defined subpopulation of T cells that modulate the immune system and maintain immune tolerance through suppression of the development of autoimmune responses to self-antigens and allergic reactions to external antigens. Reduction in the number or function of Treg cells has been suggested as a key immune abnormality underlying the development of autoimmune and allergic diseases. In vitro studies have demonstrated that purified polyvalent immunoglobulin G (IgG) from multiple healthy blood donors can exert immunomodulatory effects on Treg cells. Incubation of polyvalent human IgG with purified CD4+CD25high T cells increased the intracellular expression of interleukin (IL)-10. Intravenous administration of polyvalent human IgG induced significant expansions of CD4+ Foxp3+ Treg cells and clinical improvements in patients with autoimmune diseases. In human clinical trials, intramuscular administration of autologous total IgG significantly increased the percentage of IL-10-producing CD4+ Treg cells in the peripheral blood of healthy subjects and provided significant clinical improvements in patients with atopic dermatitis. These results suggest a clinical usefulness of polyvalent IgG-induced activation of Treg cells in human subjects. This review proposes a new hypothesis for immune tolerance mechanism by integrating the pre-existing "idiotypic network theory" and "Treg cell theory" into an "anti-idiotypic Treg cell theory." Based on this hypothesis, an "active anti-idiotypic therapy" for allergic and autoimmune diseases using autologous polyvalent IgG (as immunizing antigens) is suggested as follows: (1) Intramuscular or subcutaneous administration of autologous polyvalent IgG produces numerous immunogenic peptides derived from idiotypes of autologous IgG through processing of dendritic cells, and these peptides activate anti-idiotypic Treg cells in the same subject. (2) Activated anti-idiotypic Treg cells secrete IL-10 and suppress Th2 cell response to allergens and autoimmune T cell response to self-antigens. (3) These events can induce a long-term clinical improvements in patients with allergic and autoimmune diseases. Further studies are needed to evaluate the detailed molecular mechanism underlying polyvalent IgG-induced Treg cell activation and the clinical usefulness of this immunomodulatory therapy for autoimmune and allergic diseases.

The effects of immunoglobulin D on T cell activation and differentiation in human

[Effect of High Mobility Group Box 1 Protein on Proliferation and Apoptosis and Balance Between Th1/Th2 and Tc1/Tc2 of Lymphocytes in Vitro].

IL-10 Augments Antibody Production Inin VitroImmunized Lymphocytes by Inducing a Th2-Type Response and B Cell Maturation

Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression.

The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression.

Immunological Effect of High Mobility Group Box-1 Protein on Regulatory Dendritic Cells and Corresponding Mechanism

Effects of B7-H3 on T Lymphocytes in Different Activation States

Dissection of molecular mechanisms on increased antibody production induced by activated T cells

Immunomodulation of Human CD19+CD25high Regulatory B Cells Via Th17/Foxp3 Regulatory T Cells and Th1/Th2 Cytokines.

High Mobility Group Box 1 Protein (HMGB1) As an Immune-Modulating Factor for Polarization of Human T Lymphocytes

Sa.59. Interferon-Gamma Influences Manifestations of Autoimmune Disease by Regulating Chemokines

B7H1-Ig fusion protein activates the CD4(+) IFN-gamma receptor(+) type 1 T regulatory subset through IFN-gamma-secreting Th1 cells

IL-10 induces TGF-β secretion, TGF-β receptor II upregulation, and IgA secretion in B cells

The Effects of Vitamin D on Allergen-Induced Expression of Interleukin-13 and Interleukin-17 in Cord Blood Cd4(+)T Cells

Effects of Astragaloside IV on Th2 Lymphocyte D10 . G4 . 1 in Vitro

Effect of High Mobilityg Group Box-1 Protein on Interleukin-2 and Interleukin-2 Receptor Α Expressions in Human T Lymphocytes

The Effect of Astragaloside IV on Immune Function of Regulatory T Cell Mediated by High Mobility Group Box 1 Protein in Vitro

Immunomodulatory effects of lactobacillus and Bifidobacterium on both murine and human mitogen-activated T cells

ICAM-1 Mediated Cell-Cell Adhesion Exerts Dual Roles on Human B Cell Differentiation and IgG Production

Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

B7H1-Ig Fusion Protein Activates the CD4+ IFN-γ Receptor+ Type 1 T Regulatory Subset through IFN-γ-Secreting Th1 Cells